122 related articles for article (PubMed ID: 21814779)
21. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy.
Farshchian N; Alavi A; Heydarheydari S; Moradian N
Cancer Chemother Pharmacol; 2018 Nov; 82(5):787-793. PubMed ID: 30105459
[TBL] [Abstract][Full Text] [Related]
22. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Hershman DL; Lacchetti C; Dworkin RH; Lavoie Smith EM; Bleeker J; Cavaletti G; Chauhan C; Gavin P; Lavino A; Lustberg MB; Paice J; Schneider B; Smith ML; Smith T; Terstriep S; Wagner-Johnston N; Bak K; Loprinzi CL;
J Clin Oncol; 2014 Jun; 32(18):1941-67. PubMed ID: 24733808
[TBL] [Abstract][Full Text] [Related]
23. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.
Battaglini E; Park SB; Barnes EH; Goldstein D
Contemp Clin Trials; 2018 Jul; 70():135-138. PubMed ID: 29680317
[TBL] [Abstract][Full Text] [Related]
24. Duloxetine Protects against Oxaliplatin-Induced Neuropathic Pain and Spinal Neuron Hyperexcitability in Rodents.
Kim W; Chung Y; Choi S; Min BI; Kim SK
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29206213
[TBL] [Abstract][Full Text] [Related]
25. Protease-Activated Receptor 2 (PAR2) Expressed in Sensory Neurons Contributes to Signs of Pain and Neuropathy in Paclitaxel Treated Mice.
Kume M; Ahmad A; DeFea KA; Vagner J; Dussor G; Boitano S; Price TJ
J Pain; 2023 Nov; 24(11):1980-1993. PubMed ID: 37315729
[TBL] [Abstract][Full Text] [Related]
26. Evidence-Based Treatment of Pain in Chemotherapy-Induced Peripheral Neuropathy.
D'Souza RS; Alvarez GAM; Dombovy-Johnson M; Eller J; Abd-Elsayed A
Curr Pain Headache Rep; 2023 May; 27(5):99-116. PubMed ID: 37058254
[TBL] [Abstract][Full Text] [Related]
27. Acupuncture May Help to Prevent Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Sham-Controlled, Single-Blind Study.
Huang MC; Chang SC; Liao WL; Ke TW; Lee AL; Wang HM; Chang CP; Yen HR; Chang HH; Chen WT
Oncologist; 2023 Jun; 28(6):e436-e447. PubMed ID: 36971468
[TBL] [Abstract][Full Text] [Related]
28. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
Nepal MR; Taheri H; Li Y; Talebi Z; Uddin ME; Jin Y; DiGiacomo DF; Gibson AA; Lustberg MB; Hu S; Sparreboom A
Cancer Res Commun; 2022 Nov; 2(11):1334-1343. PubMed ID: 36506732
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D
BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138
[TBL] [Abstract][Full Text] [Related]
30. Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial.
Aghili M; Darzikolaee NM; Babaei M; Ghalehtaki R; Farhan F; Razavi SZE; Rezaei S; Esmati E; Samiei F; Azadvari M; Farazmand B; Bayani R; Amiri A
J Gastrointest Cancer; 2023 Jun; 54(2):467-474. PubMed ID: 35426033
[TBL] [Abstract][Full Text] [Related]
31. Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.
Zhou L; Liu R; Huang D; Li H; Ning T; Zhang L; Ge S; Bai M; Wang X; Yang Y; Wang X; Chen X; Gao Z; Luo L; Yang Y; Wu X; Deng T; Ba Y
EClinicalMedicine; 2021 Nov; 41():101157. PubMed ID: 34765950
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment.
Burgess J; Ferdousi M; Gosal D; Boon C; Matsumoto K; Marshall A; Mak T; Marshall A; Frank B; Malik RA; Alam U
Oncol Ther; 2021 Dec; 9(2):385-450. PubMed ID: 34655433
[TBL] [Abstract][Full Text] [Related]
33. JI017 Attenuates Oxaliplatin-Induced Cold Allodynia via Spinal TRPV1 and Astrocytes Inhibition in Mice.
Lee JH; Ji H; Ko SG; Kim W
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445514
[TBL] [Abstract][Full Text] [Related]
34. Involvement of Serotonergic System in Oxaliplatin-Induced Neuropathic Pain.
Lee JH; Kim W
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440174
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin-induced peripheral neuropathy risk factors and management in Tunisian population.
Zribi A; Nasr SB; Hamdi S; Ayari J; Fendri S; Balti M; Haddaoui A
Pan Afr Med J; 2020; 35():83. PubMed ID: 32537086
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial.
Salehifar E; Janbabaei G; Hendouei N; Alipour A; Tabrizi N; Avan R
Clin Drug Investig; 2020 Mar; 40(3):249-257. PubMed ID: 31925721
[TBL] [Abstract][Full Text] [Related]
37. Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis.
Song SY; Ko YB; Kim H; Lee GW; Yang JB; Chang HK; Kwak SM; Jung J; Lee S; Lee SY; Yoo HJ
Medicine (Baltimore); 2020 Jan; 99(1):e18653. PubMed ID: 31895829
[TBL] [Abstract][Full Text] [Related]
38. The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy.
Yoshida Y; Satoh A; Yamada T; Aisu N; Matsuoka T; Koganemaru T; Kajitani R; Munechika T; Matsumoto Y; Nagano H; Komono A; Sakamoto R; Morimoto M; Arima H; Hasegawa S
Sci Rep; 2019 Dec; 9(1):20361. PubMed ID: 31889149
[TBL] [Abstract][Full Text] [Related]
39. Patient-Reported Unmet Needs in Colorectal Cancer Survivors After Treatment for Curative Intent.
Vu JV; Matusko N; Hendren S; Regenbogen SE; Hardiman KM
Dis Colon Rectum; 2019 Jul; 62(7):815-822. PubMed ID: 31188182
[TBL] [Abstract][Full Text] [Related]
40. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy.
Hu S; Huang KM; Adams EJ; Loprinzi CL; Lustberg MB
Clin Cancer Res; 2019 Nov; 25(21):6295-6301. PubMed ID: 31123053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
